Table 3 Relationship between TRIB3 expression and clinicopathological parameters of ovarian epithelial malignant tumors
From: Down-regulation of TRIB3 inhibits the progression of ovarian cancer via MEK/ERK signaling pathway
Groups | Cases | Low | High | Positive rate (%) | P-value | High expression rate (%) | P-value | ||
|---|---|---|---|---|---|---|---|---|---|
(−) | (+) | (++) | (+++) | ||||||
FIGO stage | |||||||||
 I–II | 36 | 11 | 7 | 9 | 9 | 69.4 | P = 0.279 | 50.0 | P = 0.414 |
 III–IV | 58 | 12 | 12 | 14 | 20 | 79.3 | 58.6 | ||
Differentiation | |||||||||
 Well-moderate | 46 | 9 | 9 | 14 | 14 | 80.4 | P = 0.279 | 60.9 | P = 0.289 |
 Poor | 48 | 14 | 10 | 9 | 15 | 70.8 | 50 | ||
Lymphatic metastasis | |||||||||
 No | 60 | 16 | 9 | 18 | 17 | 73.3 | P = 0.540 | 58.3 | P = 0.229 |
 Yes | 27 | 6 | 9 | 3 | 9 | 79.3 | 41.4 | ||
 Unknowna | 7 | 1 | 1 | 2 | 3 | 85.7 | 71.4 | ||
Pathological type | |||||||||
 Serous | 46 | 10 | 12 | 10 | 14 | 78.3 | P = 0.371 | 52.2 | P = 0.786 |
 Mucinous | 10 | 4 | 1 | 2 | 3 | 60 | 50 | ||
 Endometrioid | 14 | 3 | 2 | 4 | 5 | 78.6 | 64.3 | ||
 Clear cell carcinoma | 6 | 3 | 1 | 1 | 1 | 50 | 33.3 | ||
 Poorly differentiated adenocarcinoma | 18 | 3 | 3 | 6 | 6 | 83.3 | 66. | ||